Results of univariate Cox regression analysis for overall mortality
| Variation | Non-adjustment | Model 1 | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender, male vs female | 1.66 (1.02 to 2.69) | 0.041* | – | – |
| Age (years), ≥60 vs <60 | 1.52 (1.03 to 2.26) | 0.036* | – | – |
| BMI, ≥23.12 kg/m2 vs <22.86 kg/m2 | 0.99 (0.69 to 1.43) | 0.97 | 0.95 (0.66 to 1.38) | 0.806 |
| Serum CEA level, >3.43 ng/mL vs ≤3.43 ng/mL | 1.01 (0.70 to 1.46) | 0.954 | 1.00 (0.69 to 1.45) | 0.999 |
| Serum CRP level, >7.83 µmol/L vs ≤7.83 µmol/L | 1.91 (1.31 to 2.78) | 0.001** | 1.92 (1.32 to 2.79) | 0.001** |
| Albumin level, >39.46 g/L vs ≤39.46 g/L | 1.66 (1.15 to 2.40) | 0.007** | 1.60 (1.10 to 2.31) | 0.013* |
| Neutrophil count, >4.55×109/L vs ≤4.55×109/L | 1.18 (0.82 to 1.71) | 0.367 | 1.15 (0.79 to 1.66) | 0.464 |
| Lymphocyte count, >1.63×109/L vs ≤1.63×109/L | 0.59 (0.40 to 0.85) | 0.005** | 0.61 (0.42 to 0.89) | 0.01* |
| Haemoglobin level, >133 g/L vs ≤133 g/L | 0.80 (0.56 to 1.16) | 0.244 | 0.72 (0.49 to 1.05) | 0.089 |
| Platelet count, >233×109/L vs ≤233×109/L | 1.23 (0.85 to 1.78) | 0.275 | 1.23 (0.85 to 1.78) | 0.275 |
| PNI score, >47.9 vs ≤47.9 | 0.54 (0.37 to 0.78) | 0.001** | 0.53 (0.37 to 0.77) | 0.001** |
| NLR, >2.66 vs ≤2.66 | 1.18 (0.82 to 1.71) | 0.367 | 1.20 (0.83 to 1.74) | 0.341 |
| Metastasis, yes vs no | 1.05 (0.70 to 1.57) | 0.81 | 1.10 (0.73 to 1.64) | 0.654 |
| Stage of NSCLC, IV and III vs II and I | 0.94 (0.50 to 1.75) | 0.838 | 1.05 (0.56 to 1.98) | 0.868 |
| Stage of SCLC, yes vs no | 1.33 (0.90 to 1.96) | 0.154 | 1.43 (0.97 to 2.12) | 0.074 |
| Immunotherapy, yes vs no | 0.28 (0.15 to 0.52) | <0.001*** | 0.30 (0.16 to 0.55) | <0.001*** |
| Radiation therapy, yes vs no | 0.88 (0.60 to 1.27) | 0.488 | 0.79 (0.54 to 1.16) | 0.235 |
| Use of platinum, yes vs no | 0.61 (0.15 to 2.47) | 0.483 | 0.66 (0.16 to 2.70) | 0.562 |
| Target therapy, yes vs no | 0.75 (0.42 to 1.33) | 0.323 | 0.81 (0.45 to 1.45) | 0.481 |
| Use of TKI, yes vs no | 0.77 (0.41 to 1.44) | 0.415 | 0.82 (0.44 to 1.53) | 0.534 |
| Use of VEGF inhibitor, yes vs no | 0.83 (0.47 to 1.45) | 0.518 | 0.90 (0.51 to 1.59) | 0.723 |
| Chemotherapy, AP vs others | 0.61 (0.37 to 1.00) | 0.052 | 0.66 (0.40 to 1.09) | 0.104 |
| Smoking, yes vs no | 1.23 (0.84 to 1.79) | 0.292 | 0.90 (0.56 to 1.43) | 0.645 |
| Hypertension, yes vs no | 1.13 (0.78 to 1.64) | 0.531 | 1.10 (0.75 to 1.60) | 0.622 |
| Diabetes, yes vs no | 0.90 (0.51 to 1.61) | 0.726 | 0.97 (0.54 to 1.75) | 0.927 |
| Hyperlipaemia, yes vs no | 0.79 (0.42 to 1.48) | 0.461 | 0.77 (0.40 to 1.46) | 0.421 |
| Heart failure, yes vs no | 5.61 (1.71 to 18.42) | 0.004** | 6.43 (1.94 to 21.26) | 0.002** |
| ACS, yes vs no | 0.74 (0.23 to 2.35) | 0.612 | 0.69 (0.21 to 2.21) | 0.53 |
| KPS score, >80 vs ≤80 | 0.52 (0.35 to 0.75) | 0.001** | 0.51 (0.35 to 0.74) | <0.001*** |
| miR-219-5p, ≥1.50 vs <1.50 | 0.36 (0.25 to 0.53) | <0.001*** | 0.37 (0.25 to 0.55) | <0.001*** |
Model 1: adjusted by age and gender.
***P<0.001, **p<0.01, *p<0.05.
ACS, acute coronary syndrome; AP, doxorubicin/cisplatin; BMI, body mass index; CEA, carcinoembryonic antigen; CRP, C reactive protein; KPS, Karnofsky Performance Status; NLR, neutrophil–lymphocyte ratio; NSCLC, non-small cell lung cancer; PNI, prognostic nutritional index; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.